Capricor Therapeutics Shareholders Urged to Join Securities Fraud Lawsuit

Class Action Lawsuit for Capricor Therapeutics Shareholders

On August 5, 2026, the legal firm Frank R. Cruz announced significant news for investors of Capricor Therapeutics, Inc. (CAPR). Shareholders who have experienced financial losses due to recent developments at the company now have an opportunity to take action by leading a class-action lawsuit centered around allegations of securities fraud. Investors are urged to participate before the lead plaintiff deadline on September 28, 2026.

Background of the Lawsuit

The class-action complaint alleges that between December 17, 2025, and July 26, 2026, Capricor Therapeutics made materially false statements and failed to disclose critical information regarding its business practices and future prospects. Key points of concern include the alleged changes made to the company's pre-specified statistical analysis plan related to its clinical data for Deramiocel, a treatment for Duchenne muscular dystrophy.

Specifically, the lawsuit contends that:
1. Unapproved Statistical Analysis Changes: Capricor reportedly adopted modifications to the statistical analysis plan without prior approval from the FDA before resubmitting the biologics license application (BLA) for Deramiocel.
2. Regulatory Approval Risks: The changes introduced significant risks, suggesting that the FDA might not find sufficient evidence to support the effectiveness of Deramiocel, jeopardizing potential regulatory approval.
3. Misleading Statements: Positive assertions made by the company concerning its business, operations, and growth prospects were allegedly misleading and lacked a substantial basis.

These discrepancies have prompted investors to look for recourse through legal avenues, leading to the formation of this class-action suit.

How to Participate in the Lawsuit

Investors who feel they have been impacted by the developments surrounding Capricor Therapeutics are encouraged to take action. Participation in the class-action lawsuit does not require immediate action; investors can choose to retain counsel or remain absent from the proceedings while still being eligible for potential recovery.

Interested individuals can reach out to the Law Offices of Frank R. Cruz to learn more about the lawsuit and their rights. The firm encourages affected investors to provide their mailing address, contact number, and details regarding the number of shares they purchased when reaching out. For those preferring direct communication, the office can be contacted via email or phone.

Conclusion

For those who have faced losses as shareholders of Capricor Therapeutics, the upcoming securities fraud lawsuit presents a significant opportunity to seek redress. With the looming deadline for participation, affected individuals are urged to act quickly and consider joining the class action. Additional information can also be found on the firm’s website or social media channels. As this legal endeavor progresses, it stands as a reminder to companies and investors alike about the importance of transparency and accountability in the financial markets.